AzTrials
AzTrials

Age-related Cognitive DeclineDVSNCT05155397

The Dortmund Vital Study: Impact of Biological and Lifestyle Factors on Cognitive Performace and Work Ability

An observational study of Age-related Cognitive Decline, run by Technical University of Dortmund at 1 site in Germany.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The goal of the Dortmund Vital Study is to validate previous hypotheses and to generate and validate new hypotheses about the relationship of ageing, working conditions, genetic makeup, stress, metabolic functions, cardiovascular system, immune system, and mental performance over the lifespan with a focus on healthy… Read more about this study

Who is it for?
Ages 20 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Age-related Cognitive Decline
How many people
627 participants
Where
1 siteGermany
Study dates
Apr 2016to Dec 2037
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Healthy individuals from the general population.

Who may be able to join

  • Blood thinners
  • Hormones
  • Antihypertensives
  • Cholesterol reducers
  • Normal or corrected-to-normal vision and hearing
  • Fulfill standard inclusion criteria for MRI measurements
  • Sufficient language skills

Who cannot join

  • Dementia
  • Parkinsonism
  • Stroke
  • Cardiovascular diseases
  • Bleeding tendency
  • Oncological diseases
Show all 17Show fewer
  • Schizophrenia
  • Obsessive-compulsive disorder
  • Anxiety disorders
  • Severe depression
  • Head injuries
  • Head surgery
  • Head implants
  • Eye diseases (cataract, glaucoma, blindness)
  • Accidents that limit physical fitness and mobility
  • Psychotropic drugs
  • Neuroleptics

Trial locations and contacts

1 site in 1 country.

Germany1 site

  • Technical University of Dortmund, Leibniz Research Centre for Working Environment and Human Factors

    Dortmund, 44139

Other trials in Germany

About this study

Official title: The Dortmund Vital Study: Impact of Biological and Lifestyle Factors on Cognitive Performace and Work Ability Across the Lifespan. An Interdisciplinary, Cross-sectional and Longitudinal Study

The goal of the Dortmund Vital Study is to validate previous hypotheses and to generate and validate new hypotheses about the relationship of ageing, working conditions, genetic makeup, stress, metabolic functions, cardiovascular system, immune system, and mental performance over the lifespan with a focus on healthy working adults. The Dortmund Vital Study is a multidisciplinary longitudinal study involving the Departments of Ergonomics, Immunology, Psychology and Neurosciences, and Toxicology of the Leibniz Research Centre for Working Environment and Human Factors at the TU Dortmund (IfADo) in Dortmund, Germany, as well as several national and international cooperation partners.

Read the detailed description

The Dortmund Vital Study is designed as a combined cross-sectional and longitudinal study. About 600 subjects aged between 20 and 70 years will participate. A wide range of demographic, psychological, behavioral, sensory, cardiovascular, biochemical, immunological and biochemical data, a comprehensive EEG-based cognitive test battery as well as structural and functional magnetic resonance imaging (MRI) have been included in the study. Specifically, parameters obtained by MRI and EEG-related measures can be evaluated as a function of polygenic scores, metabolic products, concentration of immune cells, immune age and infections, such as Toxoplasmosis or COVID-19 that are largely unexplored. The same is true for environmental and lifestyle factors that impact on brain activity and behavior.

The initial testing has been conducted between 2016 and 2021 and will be repeated every five years (three follow-up measures until 2035).

The study will shed light on sources of large inter-individual differences in cognitive functioning with increasing age and reveal biological and lifestyle markers contributing to work ability, longevity and healthy aging on the one hand, and on risk factors for cognitive decline, mild cognitive impairment or even dementia on the other.

Keywords
Cognitive Ageing, Occupational Health, Neuropsychology, Metabolism, Cardiovascular System, Behavioral Genetics, Immunology, EEG, MRI, psychoneuroendocrinology, Infectious diseases, Cognitive Neuroscience
Medical subject headings
Communicable Diseases

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in performance on global cognitive composite score assessed by neuropsychological tests

    Change in performance on global cognitive composite score based on measures from neuropsychological tests: Digit-Span forward and backward, semantic memory in written and spoken versions (Word-Fluency), selective attention and attentional endurance (D2-R), crystallized intelligence (Multiple Choice Vocabulary Test), general cognitive status (Mini-Mental-State-Examination; MMSE), different aspects of verbal memory like learning performance and retrieval (Verbal Learning and Memory Tests; VLMT), psychomotor performance and speed of processing (Digit-Symbol-Test), interference control and inhibition (Stroop Test), task switching (Trail-Making-Test; TMT-A and TMT-B), two subtests from the performance testing system measuring logical reasoning and spatial rotation, and fluid intelligence assessed by Raven's Progressive Matrices.

    Measured: Baseline and 5, 10, 15 years

  2. Change in attentional performance and perceptual control as assessed by a computerized Bar Task

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in attentional performance and perceptual control assessed by the Bar Task.

    Measured: Baseline and 5, 10, 15 years

  3. Change in vigilance control as assessed by a computerized Psychomotor Vigilance Test

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in a Psychomotor Vigilance Test.

    Measured: Baseline and 5, 10, 15 years

  4. Change in stimulus-response compatibility and conflict processing assessed by the computerized Simon Task

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in the Simon task.

    Measured: Baseline and 5, 10, 15 years

  5. Change in updating and strategy learning assessed by the computerized AX-CPT Task

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in the AX-CPT task.

    Measured: Baseline and 5, 10, 15 years

  6. Change in speech understanding and auditory distractibility assessed by computerized Speech-In-Noise perception task

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in the Speech-in-noise perception task.

    Measured: Baseline and 5, 10, 15 years

  7. Change in working memory assessed by the computerized N-back Task

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in the N-back task.

    Measured: Baseline and 5, 10, 15 years

  8. Change in cue and memory-based task switching assessed by the computerized Task Switching Paradigm

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in the cue- and memory based task switching.

    Measured: Baseline and 5, 10, 15 years

  9. Change in auditive attention and distractibility assessed by the computerized Auditory Distraction Task

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in the Auditory Distraction Task.

    Measured: Baseline and 5, 10, 15 years

  10. Change in susceptibility to interference and the capacity to inhibit irrelevant stimuli assessed by the computerized Stroop Task

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in the Stroop Task.

    Measured: Baseline and 5, 10, 15 years

  11. Change in inhibitory control of prepotent responses assessed by the computerized Go/NoGo Task

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in the Go/NoGo Task.

    Measured: Baseline and 5, 10, 15 years

  12. Change in spatial selective attention assessed by the computerized Visual Search Task

    Changes in behavioral (speed and accuracy) and electroencephalogram (EEG) data in the Visual Search Task.

    Measured: Baseline and 5, 10, 15 years

  13. Change in Work Ability Index

    Change in work ability assessed by Work Ability Index (WAI). WAI assess physical and psychological risks to avoid work-related disabilities and early retirement. The index is determined by the employees' answers related to work demands, individual health status and physical and psychological capacities. The total score of WAI is calculated by summing up scores of seven dimensions. The work ability ranged between 7 (insufficient) and 49 points (best work ability).

    Measured: Baseline and 5, 10, 15 years

Secondary outcomes (27)

  1. Change in resting state EEG activity

    Change in resting state EEG activity measured for 2 minutes with eyes open, and 2 minutes with eyes closed.

    Measured: baseline and 5, 10, 15 years

  2. Change in brain function MRI

    Changes in functional magnetic resonance imaging assessed by resting state MRI.

    Measured: 5, 10, 15 years

  3. Change in brain structure MRI

    Changes in structural resonance imaging assessed by multi-shell diffusion-weighted imaging (DWI).

    Measured: 5, 10, 15 years

  4. Change in Depressive Symptoms

    Change in total score using the Becks Depression Inventory (BDI).

    Measured: Baseline and 5, 10, 15 years

  5. Change in Burnout Symptoms

    Change in total score using the Maslach Burnout Inventory (MBI-D) with 6-point Likert-type scale ranging from 1 (never) to 6 (always), total scores: 14 - 84. Higher scores indicate more severe symptoms.

    Measured: Baseline and 5, 10, 15 years

  6. Change in Burnout Symptoms

    Change in total score using the Oldenburg Burnout Inventory (OLBI). 4-point Likert-type scale ranging from 1 (strongly agree) to 4 (strongly disagree), total scores: 8 - 32. Higher scores indicate more severe symptoms.

    Measured: Baseline and 5, 10, 15 years

  7. Change in Psychosocial Stress Symptoms

    Change in total score using the Psychosocial Stress Questionnaire (PSQ-20).

    Measured: Baseline and 5, 10, 15 years

  8. Change in Chronic Stress Symptoms

    Change in chronic stress symptoms assessed by the Trier Inventory of Chronic Stress (TICS), consisting of several dimensions: Work Overload, Social Overload, Pressure to Perform, Work Discontent, Demands from work, Lack of Social Recognition, Social Tensions, Social Isolation, Chronic Worrying, and a 12 Item Screening-Scale (SSCS) that provides a score for general stress.

    Measured: Baseline and 5, 10, 15 years

  9. Change in Psychosocial Work Demands

    Change in total score in the Copenhagen Psychosocial Questionnaire (COPSOQ III) that consists of several dimensions: cognitive and physical demands at work, job control, influence at work, developmental possibilities, interpersonal relations, leadership, and strain.

    Measured: 5, 10, 15 years

  10. Change in Self-Control at work

    Change of the psychosocial demands at work assessed by the scale Self-Control at Work.

    Measured: Baseline and 5, 10, 15 years

  11. Change in Cognitive Failures in the Daily Life

    Change in cognitive failures in daily life assessed by the Cognitive Failure Questionnaire (CFQ).

    Measured: Baseline and 5, 10, 15 years

  12. Change in Positive and Negative Affect

    Change in scores of positive and negative affect. The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire that consists of two 10-item scales to measure both positive and negative affect.

    Measured: Baseline and 5, 10, 15 years

  13. Change in Quality of Life

    Change in total score of the quality of life questionnaire (WHOQoL-BREF), consisting of dimensions: physical, psychological, social, environmental, and global quality of life.

    Measured: Baseline and 5, 10, 15 years

  14. Change in sociodemographic parameters

    Change in different sociodemographic aspects like marital status, occupational status, nutrition, leisure activities, alcohol drinking, frequency of social contacts, using of electronic media etc. Qualitative data will be categorized.

    Measured: Baseline and 5, 10, 15 years

  15. Change in self-reported physical activity

    Change of the self-reported physical activity (Lüdenscheid Physical Activity Questionnaire) in minutes per week.

    Measured: Baseline and 5, 10, 15 years

  16. Change in lateralization and motor functions

    Change in total score of the Perdue Pegboard Test, assessing lateralization and motor functions.

    Measured: Baseline and 5, 10, 15 years

  17. Change of cytokines concentration in serum

    Change of concentration of cytokines in serum (pg/ml): (IL-1b, IFN-alpha, IFN-gamma, TNF-alpha, MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33).

    Measured: Baseline and 5, 10, 15 years

  18. Change of functional activiy of T cells and Natural Killer cells

    Change of functional activities of T cells and natural killer cells in %.

    Measured: Baseline and 5, 10, 15 years

  19. Change of peripheral blood mononuclear cells concentration

    Change of peripheral blood mononuclear cells concentration (pg/ml): (PBMC; CD14 positive monocytes).

    Measured: Baseline and 5, 10, 15 years

  20. Change in physical performance

    Change of physical fitness assessed by bicycle ergometer and a physical work capacity cycle test (PWC-130) to predict the absolute power output (in Watt) at a projected heart rate of 130 beats per minute. A relative power output is calculated by the power-to-weight ratio (Watt/kg).

    Measured: Baseline and 5, 10, 15 years

  21. Change in cardiovascular parameters

    Diastolic and systolic blood pressure (mm/Hg) and pulse (bpm) measured during rest and during cycle ergometry.

    Measured: Baseline and 5, 10, 15 years

  22. Change in electrocardiography

    Change in electrocardiogram (ECG) measured during rest and during cycle ergometry.

    Measured: Baseline and 5, 10, 15 years

  23. Change in antibody concentrations of Toxoplasma gondii in serum

    Change of concentration of Toxoplasma gondii IgG antibodies (pg/ml) in serum to assess the severity of latent toxoplasmosis infection.

    Measured: Baseline and 5, 10, 15 years

  24. Change in antibody concentrations of COVID-19 in serum

    Concentration of COVID-19 antibodies (pg/ml) in serum to assess the intensity of immunological response to potential SARC-CoV-2 infection or response to vaccination.

    Measured: 5, 10, 15 years

  25. Change in metabolic parameters in blood

    Change in metabolic parameters in serum (pg/ml): concentration of ammonia, leucocytes, erythrocytes, hematocrit, monocytes, creatinine, lymphocytes, cell volume, thrombocytes, triglycerides, cholesterol, high- and low-density lipoprotein cholesterol, glycosylated hemoglobin, glucose, C-reactive protein and creatinine are measured in venous blood.

    Measured: Baseline and 5, 10, 15 years

  26. Change of metabolic parameters in urine

    Change in metabolic parameters in urine (pg/ml): concentartion of creatinine and calcium oxalate.

    Measured: Baseline and 5, 10, 15 years

  27. Change of endocrine parameter

    Change of hair cortisol concentration (pg/mg) as an index of long-term stress.

    Measured: Baseline and 5, 10, 15 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Dec 2021
  2. Study startApr 2016
  3. Primary completionDec 2035 (estimated)
  4. Study completionDec 2037 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
627 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05155397
Sponsor's protocol ID
A93-3
Acronym
DVS
Status last verified
Sep 2026
First submitted
16 Nov 2021
Last updated
2 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: After primary analyses and publication of the main results the data and the scripts used for data analyses will be made available in repositories for secondary analyses. The transfer agreement will be prepared by the coordinators of the Dortmund Vital Study in consultation with the IfADo Research Data Management Unit.

Publications

  • Schwaba T, Clapp Sullivan ML, Akingbuwa WA, Ilves K, Tanksley PT, Williams CM, Dragostinov Y, Mallard TT, Tubbs JD, Liao W, Ackerman LS, Fealy JCM, Hemani G, de la Fuente J, Smith GD, Gupta P, Stein MB, Gelernter J, Levey DF, Vosa U, Ausmees L, Realo A; Estonian Biobank Research Team; Vaht M, Allik J, Esko T, Mottus R, Vainik U, Jonsdottir GA, Thorleifsson G, Gunnarsson AF, Bjornsdottir G, Thorgeirsson TE, Stefansson H, Stefansson K, Cheesman R, Qin Q, Corfield EC, Ask H, Torvik FA, Ystrom E, Tesli M, Boomsma DI, de Geus EJC, Hottenga JJ, Melo DC, Snieder H, Hartman CA, Xia C, Campbell A, Luciano M, Deary IJ, Hill WD, Jang SK, Vrieze SI, Abecasis G, Lupton MK, Mitchell BL, Viher PV, Colodro-Conde L, Martin NG, Medland SE, Derks EM, Wormington B, Kaprio J, Silventoinen K, Palviainen T, Musial A, Rimfeld K, Plomin R, Malanchini M, Dick DM, Aliev F; COGA Collaborators; Spit for Science Working Group; Wesseldijk LW, Ullen F, Mosing MA, Kranzler HR, Nunez Y, Beck S, Polimanti R, Edwards T, Giannelis A, Willoughby EA, Lee JJ, McGue M, Terracciano A, Marongiu M, Fiorillo E, Cucca F, Sutin AR, van der Most PJ, Oldehinkel AJ, Kretschmer T, Shabalin AA, Docherty AR, Krueger RF, Freilich CD, Mishra BH, Lehtimaki T, Raitakari OT, Kahonen M, Saarinen A, Dobewall H, Keltikangas-Jarvinen L, Berger K, Herrera-Rivero M, Streit F, Awasthi S, Witt SH, Tuhkanen J, Raikkonen K, Eriksson JG, Lahti J, Davies G, Redmond P, Taylor A, Corley J, Russ TC, Ciullo M, Nutile T, Ding J, Qian Y, Tanaka T, Ferrucci L, Zillich L, Sirignano L, Harden KP, Genc E, Gajewski PD, Getzmann S, Fraenz C, Schneider Penate JE, Lis S, Hall ASM, Schmahl C, Herpertz SC, Abdellaoui A, Nivard MG, Tucker-Drob EM. Robust inference and correlates from genetic associations with personality. Nature. 2026 Sep 2:10.1038/s41586-026-10992-9. doi: 10.1038/s41586-026-10992-9. Online ahead of print.

    PubMed 42686911

  • Mundorf A, Merklein SA, Reinke P, Peterburs J, Getzmann S, Gajewski PD, Larra M, Wascher E, Ocklenburg S. Effects of motor activity versus cognitive demand on asymmetries in EEG frequency bands and their relation to handedness. Front Hum Neurosci. 2026 Jul 8;20:1796350. doi: 10.3389/fnhum.2026.1796350. eCollection 2026.

    PubMed 42487830

  • Metzler YA, Schade HM, Nitsche MA, Wascher E, Getzmann S, Gajewski PD, Melo L. Beyond composite scores in chronotype assessment: item-level predictive patterns in the Morningness-Eveningness Questionnaire. Sci Rep. 2026 Jun 4;16(1):17347. doi: 10.1038/s41598-026-54301-w.

    PubMed 42243262

  • Jungeblut HM, Genc E, Burke M, Gajewski PD, Getzmann S, Wascher E, Schubert AL. The latent organization of white matter microstructure and its relation to fluid intelligence. Imaging Neurosci (Camb). 2026 Mar 19;4:IMAG.a.1167. doi: 10.1162/IMAG.a.1167. eCollection 2026.

    PubMed 41868967

  • Sabo M, Varlet M, Wascher E, Gajewski PD, Grootswagers T. Multiple partially overlapping neural modules orchestrate conflict processing. Imaging Neurosci (Camb). 2026 Feb 20;4:IMAG.a.1135. doi: 10.1162/IMAG.a.1135. eCollection 2026.

    PubMed 41738010

  • Brode P, Claus M, Getzmann S, Golka K, Hengstler JG, Reinders J, Wascher E, Watzl C, Gajewski PD. Latent Toxoplasma gondii Infection Does Not Modulate Immune Aging in a Cross-Sectional Working-Age Population Study. Biomolecules. 2025 Dec 30;16(1):55. doi: 10.3390/biom16010055.

    PubMed 41594595

  • Engler R, Stammen C, Arnau S, Schneider Penate J, Metzen D, Digutsch J, Gajewski PD, Getzmann S, Fraenz C, Reinders J, Voelkle MC, Streit F, Ocklenburg S, Schneider D, Burke M, Hengstler JG, Watzl C, Nitsche MA, Kumsta R, Wascher E, Genc E. Electrophysiological resting-state signatures link polygenic scores to general intelligence. Sci Rep. 2025 Nov 21;15(1):41170. doi: 10.1038/s41598-025-26778-4.

    PubMed 41272243

  • Gajewski PD, Brode P, Claus M, Golka K, Hengstler JG, Reinders J, Watzl C, Wascher E, Getzmann S. Changes of cognitive functions and proinflammatory cytokines across the lifespan in latent Toxoplasma gondii infection. Brain Behav Immun Health. 2025 Sep 15;49:101105. doi: 10.1016/j.bbih.2025.101105. eCollection 2025 Nov.

    PubMed 41018675

  • Gajewski PD, Brode P, Claus M, Golka K, Hengstler JG, Watzl C, Wascher E, Getzmann S. The association between hair cortisol and burnout is moderated by age, psychosocial, and immunological markers. Brain Behav Immun Health. 2024 Nov 23;43:100909. doi: 10.1016/j.bbih.2024.100909. eCollection 2025 Feb.

    PubMed 39717874

  • Kleinert T, Nash K, Koenig T, Wascher E. Correction: Normative Intercorrelations between EEG Microstate Characteristics. Brain Topogr. 2024 Mar;37(2):270. doi: 10.1007/s10548-023-01012-4. No abstract available.

    PubMed 37861818

  • Kleinert T, Nash K, Koenig T, Wascher E. Normative Intercorrelations Between EEG Microstate Characteristics. Brain Topogr. 2024 Mar;37(2):265-269. doi: 10.1007/s10548-023-00988-3. Epub 2023 Jul 14.

    PubMed 37450085

  • Kleinert T, Koenig T, Nash K, Wascher E. On the Reliability of the EEG Microstate Approach. Brain Topogr. 2024 Mar;37(2):271-286. doi: 10.1007/s10548-023-00982-9. Epub 2023 Jul 6.

    PubMed 37410275

  • Getzmann S, Arnau S, Gajewski PD, Wascher E. Auditory distraction, time perception, and the role of age: ERP evidence from a large cohort study. Neurobiol Aging. 2024 Dec;144:114-126. doi: 10.1016/j.neurobiolaging.2024.09.012. Epub 2024 Sep 20.

    PubMed 39316947

  • Getzmann S, Gajewski PD, Schneider D, Wascher E. Resting-state EEG data before and after cognitive activity across the adult lifespan and a 5-year follow-up. Sci Data. 2024 Sep 10;11(1):988. doi: 10.1038/s41597-024-03797-w.

    PubMed 39256413

  • Mundorf A, Getzmann S, Gajewski PD, Larra MF, Wascher E, Genc E, Ocklenburg S. Phenotyping in clinical laterality research: a comparison of commonly used methods to determine mixed-handedness and ambidexterity. Laterality. 2024 May;29(3):331-349. doi: 10.1080/1357650X.2024.2370871. Epub 2024 Jul 5.

    PubMed 38968414

Questions about this trial

What is this clinical trial studying?

An observational study of Age-related Cognitive Decline, run by Technical University of Dortmund at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in performance on global cognitive composite score assessed by neuropsychological tests (time frame: Baseline and 5, 10, 15 years). The study lists 13 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05155397, which also lists 33 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in